Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.

ABSTRACT: The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as "biobetters" or "value-added medicines," are now reaching the market. These innovative biologics differ from the reference product by offering additional clinical or non-clinical benefits. We discuss these innovative biologics with reference to CT-P13, initially available as an intravenous (IV) biosimilar of reference infliximab. A subcutaneous (SC) formulation, CT-P13 SC, has now been developed. Relative to CT-P13 IV, CT-P13 SC offers clinical benefits in terms of pharmacokinetics, with compar

SUBMITTER: Kim H 

PROVIDER: S-EPMC7889098 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature